Ultragenyx Pharmaceutical Inc. (RARE)

From the record

Ultragenyx Pharmaceutical Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Ultragenyx Pharmaceutical Inc.'s 10 filed years say what it did: revenue went from $133 thousand in fiscal 2016 to $673 million in fiscal 2025, up 158% a year; it rose in 9 of 9 years; it never fell from a peak; net income was positive in 0 of 10 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Ultragenyx Pharmaceutical Inc.'s shareholders' equity was below zero, so the profit on it is not read. Leverage: it owed about 105 cents per dollar of assets, and net share issuance: its share count grew 9.0% over the year (the filed statements).

From the record

Ultragenyx Pharmaceutical Inc.'s standing among 315 graded names in its industry family: revenue of $673 million in fiscal 2025 ranks in the top 16% by size; a net margin of -85.4% ranks in the top 45%; revenue growth of 22.8% a year over the last 3 filed years ranks in the top 36% (its annual reports).

From the record

Ultragenyx Pharmaceutical Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Kakkis, Emil D (President & CEO, as filed), filing under that title since 2014-01-30, 12.8 years (top 9% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 10.4 years (top 6%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (top 16%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Ultragenyx Pharmaceutical Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $421 million against no long-term debt tagged leaves 27.5% of its assets as net cash, bottom 50% of its family; cash from operations less capital spending is -70.1% of revenue (top 47%); research spending of 111.4% of revenue (top 49%) (its annual report).

From the record

Ultragenyx Pharmaceutical Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 22.8% a year over the last three filed years against 158% over all 10, slowing (bottom 1% of its family); the newest year grew 20.2% (top 38%); research spending grew 2% a year (top 49%); capital spending grew -62.7% a year (bottom 11%) (its annual reports). Ultragenyx Pharmaceutical Inc. reported 2 product lines in fiscal 2025: Product at $369 million (55%), Royalty at $304 million (45%); 2 of 2 grew against the year before (its annual report).

From the record

Ultragenyx Pharmaceutical Inc.'s newest year against its own record: revenue of $673 million in fiscal 2025 came in 3.2% below the $695 million its prior three years' pace pointed to (bottom 47% of its family); net income of $575 million against a prior three-year average of $628 million (bottom 46%); a net margin of -85.4% against losses larger than its revenue before (top 36%) (its annual reports).